Profound Medical Corp. (PROF) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Profound had cash of $24.8 million. As we will discuss later in the call, we believe that we are now on a path to profitable growth. In keeping with that, we expect our cash barn to decline and eventually turn cash flow positive. As our revenue continues to grow and our margins remain high. That said, we have recently received some inquiries about potential future financing plans and if we have a shelf registration statement filed in the U.S. With respect to our thoughts on future financing, while we have not made any current plans, we'd like to assure investors that we'll continue to be opportunistic with the goal of limiting shareholder dilution as much as is practicable. And with respect to a shelf, we do not currently have one in place, but plan to file a S3 later this evening as a matter of good corporate housekeeping to keep our options open as we move forward with our financial growth. With that, I will now turn the call over to Matthew for an update on clinical and development activities. Thank you, Rashid, and good afternoon. Last quarter, we initiated the pilot release of our new Tulsa AI volume reduction software, which is specifically designed to shrink benign enlarged prostates primarily caused by the condition known as BPH. I am delighted to announce today that the full product release will be launched at this year's annual meeting of the Radiological Society of North America, or RSNA, which is taking place in Chicago at the end of this month. The new volume reduction software leverages AI-powered planning and accelerated ablation, together with the same Tulsa hardware, the same regulatory indication for use, and the same reimbursement codes, to provide fast and efficient workflows which are on par with mainstream BPH treatment options. The PI release h...